An Efficacy and Safety Study for JNS001 in Adults With Attention-Deficit Hyperactivity Disorder

NCT01323192 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

284

Enrollment

INDUSTRY

Sponsor class

Conditions

Attention-Deficit Hyperactivity Disorder

Interventions

DRUG: JNS001
DRUG: Placebo

Sponsor

Janssen Pharmaceutical K.K.